Hyperion DeFi, Inc. (HYPD) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Hyperion DeFi Inc (HYPD) 3-Minute Overview > **💡 One-Sentence Summary** > > Hyperion DeFi is a tiny, ultra-speculative U.S. pharma/biotech-style name with collapsing revenue, huge losses, and a very volatile stock that just had a sentiment flip from “avoid” to “selective buy” among analysts. > **📍 Basic Profile** > > Market Cap **$33.8 million** · Pharmaceuticals · NASDAQ · Price **$4.14** > **⚡ 3 Things You Should Know** > > 1. ⚠️ **Extreme fundamentals stress:** Revenue has shrunk about **84% over 3 years** with margins so negative they’re essentially off the charts (net margin around **-4,800%**), which usually means the core business model is not working at current scale. > > 2. 🎢 **High-risk trading vehicle, not a steady business:** A **beta > 4** and a share price that has crashed from a **$16.35 high to $4-ish** tell you this trades more like a story/turnaround play than a fundamentals-driven compounder. > > 3. 🔄 **Sentiment whiplash + insider buying:** Street views flipped from mostly **Sell/Strong Sell** to mostly **Buy/Strong Buy** in 6–9 months, and several insiders have been **net buyers recently**—together this suggests a narrative of “turnaround hope,” but with very little hard financial evidence yet. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |------------------|----------------------------|---------| > | Profitability | Weak👎 | Net margin about **-4,868%**, gross margin deeply negative | > | Growth Rate | Stagnant/Declining🐢 | 3-year revenue growth **-84%** | > | Financial Health | Moderate💛 | Current ratio OK (~2.3), but leverage and negative cash economics are concerning | > | Valuation | [Data unavailable] | No PE (loss-making), P/S ~**98x** on shrunken sales looks story-driven | --- ## 📋 Layer 2: 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Develops/sells pharma/biotech-type products (per industry classification), likely early-stage or niche, making money (in theory) from drug sales or licensing—but current numbers show very little revenue and very large operating losses. **Revenue Breakdown:** (Not provided in the data.) | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Core pharma/biotech operations | [Data unavailable] | ↓ | Overall revenue has plunged; likely no stable, diversified revenue base. | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------------|--------------|-----------------|----------------| | Gross Margin | **-798%** | Far below avg | Cost of goods + overhead massively exceed revenue; typical of very small or distressed operations. | | Net Margin | **-4,869%** | Extreme bottom | For every $1 of revenue, they lose ~$48—this is “venture-stage burn,” not a sustainable business. | | ROE | **9.36%** | Looks “OK” but misleading | Positive ROE with such bad margins suggests one-off items/accounting quirks; not a sign of real earnings strength. | **Takeaway:** On income-statement quality alone, this is essentially a **speculative R&D project** rather than a functioning, profitable company right now. --- ### 📈 How’s the Growth? **Growth Assessment:** **Slowing / Shrinking** | Metric | Latest | vs Last Years | Trend | |-----------------|-------------------|-----------------------|-------| | Revenue Growth | 3-year: **-84%** | Huge drawdown | Clear decline | | Profit (EPS) | Still negative | Some quarter-on-quarter “beats” | Losses narrowing vs expectations recently | **Earnings Surprise History:** - 2025-03-31: **-1.63 vs -9.79 est** → big positive surprise (loss much smaller than feared). - 2024-12-31: **-6.93 vs -7.34 est** → small beat. - 2024-09-30: **-8.8 vs -10.88 est** → decent beat. - 2024-06-30: **-16.8 vs -12.24 est** → big miss. **Growth Quality:** The recent “beats” mostly mean: - Analysts had very low expectations (huge losses), - The company lost **less** than feared, but still a lot. There’s no evidence yet of **healthy, organic top-line growth**—just slightly improved loss trajectory from a very bad base. --- ### 💰 Financial Health Check **One Sentence:** Think of HYPD like someone who has some cash and can pay near-term bills, but has **big debts and spends far more than they earn**, living on borrowed time and capital. | Metric | Value | Safe Zone | Assessment | |-----------------------|------------|--------------|------------| | Debt-to-Equity | **1.59x** | <0.6 ideal | ⚠️High – fairly leveraged for a tiny, loss-making company. | | Long-Term D/E | **1.00x** | <0.5 better | ⚠️Elevated – meaningful long-term obligations. | | Current Ratio | **~2.25** | >1.5 healthy | ✅Able to cover short-term liabilities on paper. | | Quick Ratio | **0.15** | >1.0 wanted | 🚨Very low – liquid assets (cash/receivables) likely thin. | | Interest Coverage | **-49x** | >3x safe | 🚨Earnings don’t cover interest at all; operations are deeply loss-making. | | Cash Flow | [Not given]| >0 ideal | Likely negative given margins and losses. | **Takeaway:** Balance sheet can handle **near-term payables**, but structurally this looks like a company that will **need ongoing funding (equity or debt)** if it doesn’t turn the business around quickly. --- ### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: **$2.80** - 52-Week High: **$16.35** - Current: **$4.14** Position within range: \[ \text{Position} = \frac{4.14 - 2.80}{16.35 - 2.80} \approx 9.3\% \] So it’s trading **near the low end** of its 52-week range. | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|-----------|-----------|------------| | Criteria | 0–33% | 33–66% | 66–100% | | **Current** | ● (~9%) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |-----------------|-----------------------|------------------------|------------| | PE (TTM) | **N/A (loss-making)** | 5-year avg N/A | Not meaningful. | | P/S (TTM) | **~98x** | Most small biotechs <10x | Extremely high on current revenues. | | vs Peers (PE) | N/A | N/A | Loss-making. | **What the Current Valuation is Betting On:** At a **~98x P/S** despite collapsing sales, the market is **not** valuing HYPD on today’s fundamentals. It’s implicitly betting on: - Some **future inflection** (pipeline success, partnership, regulatory win), or - A **“lottery ticket” outcome** where a single event massively re-rates the stock. If that doesn’t materialize, even at ~$4 the stock can still go much lower (or get diluted heavily). --- ### 📰 Any Recent News? (The two listed items are generic “top analyst calls” headlines and don’t give company-specific details, but they do indicate HYPD is on analyst radar.) | Date | Event/Headline | Impact | |------------|--------------------------------------------------------|--------| | 2025-xx-xx | Appears in “Wall Street’s top analyst calls” lists | Neutral → Signals some Street attention but no clear directional news in the snippet. | Nothing in the provided news suggests a clear fundamental catalyst yet; likely the real drivers are **earnings, pipeline updates, or financings** that are not included in this dataset. --- ## 📊 Layer 3: 3-Minute Complete Analysis ### I. Detailed Financial Data **Profitability Trends:** (We only have latest metrics; past years not provided, so treat this as a snapshot.) | Metric | This Year (TTM) | Last Year | Year Before | 3-Year Trend | |------------|------------------|-----------|-------------|--------------| | Gross Margin | **-798%** | [N/A] | [N/A] | [Data unavailable] | | Net Margin | **-4,869%** | [N/A] | [N/A] | [Data unavailable] | | ROE | **9.36%** | [N/A] | [N/A] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |-----------------|-----------|-----------|-------------|--------------| | Revenue Growth | **-84% (3Y)** | [N/A] | [N/A] | Clear decline from earlier period | | Profit Growth | Negative EPS, improving vs estimates | [N/A] | [N/A] | Losses still substantial | | EPS Growth | [N/A] | [N/A] | [N/A] | [Data unavailable] | Overall picture: **shrinking business, still burning a lot of money.** --- ### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter End | EPS Expected | EPS Actual | Surprise | |---------------|-------------:|-----------:|----------------| | 2025-03-31 | -9.79 | -1.63 | **+83% beat 😀** (loss much smaller than expected) | | 2024-12-31 | -7.34 | -6.93 | **+6% beat 😀** | | 2024-09-30 | -10.88 | -8.80 | **+19% beat 😀** | | 2024-06-30 | -12.24 | -16.80 | **-37% miss 😟** | **Earnings Trend Interpretation:** - After a **big miss in mid-2024**, the company has put together **three consecutive beats**, which often: - Improves sentiment, - Attracts speculative traders, - Helps “turnaround” narratives. - But, all four quarters are **still firmly in the red**; you’re seeing **less-bad** results, not actual profitability. --- ### III. What the Market Thinks **Analyst Ratings Over Time:** | Period | Strong Buy | Buy | Hold | Sell | Strong Sell | |------------|------------|-----|------|------|-------------| | 2026-01-01 | 2 | 5 | 1 | 0 | 0 | | 2025-10-01 | 0 | 0 | 5 | 1 | 2 | | 2025-08-01 | 0 | 0 | 5 | 1 | 2 | | 2025-07-01 | 0 | 0 | 5 | 1 | 2 | **Interpretation:** - Mid-2025: Consensus was basically **“avoid or sell”** (3 out of 8 ratings were Sell/Strong Sell, zero Buys). - Early 2026: Swung to **overwhelmingly positive** (7 of 8 are Buy/Strong Buy). So the Street has **dramatically re-rated the story**—likely based on some pipeline/deal/strategic update not detailed here, plus better-than-feared losses. **Target Price:** (Not provided explicitly. So upside/downside vs target is unknown.) **Insider Activity (last few months):** | Name | Net Change | Code | Comment | |---------------------|-----------:|------|---------| | Rubenstein Robert | +75,000 | A | Award/acquisition – likely positive, shows added exposure. | | Knox David R. | +27,950 | P | Open market/plan purchase. | | Jung Hyunsu | -82,324 | F | Usually tax-related or share withholding, not necessarily bearish. | | Strahlman Ellen R | Multiple + | P | Series of purchases → building position. | | Walters Happy David | +61,930 | P | Purchase, likely confidence signal. | Overall: **Net insider buying**, especially through “P” (purchase) transactions, which is **usually a positive signal**—management is either optimistic about the turnaround or supporting the stock during a tough patch. --- ### IV. Key Risk Alerts 1. **Business Viability Risk:** Revenue down ~84% over 3 years with **massive negative margins** suggests the current commercial model doesn’t work. → If new products, partnerships, or funding don’t change this, the company may face **continuous dilution, restructuring, or worse.** 2. **Financing & Dilution Risk:** High leverage, poor interest coverage, and ongoing losses mean HYPD likely needs **fresh capital**. → This often leads to **equity raises at low prices**, diluting existing shareholders and capping upside. 3. **Volatility & Sentiment Risk:** A **beta > 4**, a share price >80% below its 52-week high, and a sharp shift in analyst views all scream **sentiment-driven swings**. → Small news (good or bad) can trigger **large price moves**; short-term traders can get whipsawed, and long-term investors need strong conviction and risk tolerance. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Hyperion DeFi (HYPD) is a tiny, highly speculative pharma/biotech-style stock with collapsing revenue and very heavy losses, trading near its 52-week low but at a sky-high sales multiple. > **Key strength:** The main positives are improving “less-bad” earnings vs expectations, a recent swing in analyst sentiment to mostly Buy, and visible insider buying that hints at internal confidence in a turnaround or key catalyst. > **Key risk:** Fundamentally the business is still in deep red-ink territory with weak cash metrics and leverage, so without a real operational inflection, the risk of further downside and dilution is significant. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis of competitive advantages and pipeline durability. > • Want to check for hidden landmines (e.g., pending lawsuits, going-concern warnings)? → Try【Muddy Mode】for risk screening. > • Considering it as a high-growth lottery ticket and want to see if the upside justifies the risk? → Try【Musk Mode】for scenario-based valuation and probability-weighted outcomes.